Court orders temporary halt on Sun Pharma's $3.2 bln takeover of Ranbaxy

MUMBAI Thu May 1, 2014 12:09am IST

A Ranbaxy office building is pictured in Mohali May 14, 2013. REUTERS/Ajay Verma/files

A Ranbaxy office building is pictured in Mohali May 14, 2013.

Credit: Reuters/Ajay Verma/files

Related Topics

Stocks

   

MUMBAI (Reuters) - A court has temporarily halted generic drugmaker Sun Pharmaceutical Industries Ltd's(SUN.NS) $3.2 billion takeover of rival Ranbaxy Laboratories Ltd(RANB.NS) until it decides on a petition for a probe into alleged insider trading.

Last week, two individuals filed the petition in the high court of Andhra Pradesh, requesting the court ask the market regulator and the two main stock exchanges to halt the deal and order the probe. A copy of the petition was seen by Reuters on Wednesday.

The court then ordered an "interim status quo" on the deal and asked all the involved companies, the regulator, and the stock exchanges for details, according to an order dated April 25 and seen by Reuters on the court's website on Wednesday.

Ranbaxy shares jumped 24 percent and trading volume tripled in three sessions ahead of the companies' announcement that Sun Pharma would buy the loss-making company from Japan's Daiichi Sankyo Ltd (4568.T).

The Indian market regulator said this month it was seeking information from Ranbaxy and Sun Pharma on the transaction and would ask for stock exchange trading data after receiving "multiple complaints".

Sun Pharma and Ranbaxy are listed on both the National Stock Exchange and the Bombay Stock Exchange.

Sun Pharma said in a statement the company had not received any communication related to the court order. It also said that it had not violated any rules.

"The matter related to purchase of shares of Ranbaxy Laboratories Ltd does not violate Insider Trading Rules," Sun said, adding it would take "appropriate action" on the petition as advised by its lawyers.

Ranbaxy did not immediately respond to an email requesting comment. A spokesman for the market regulator, the Securities and Exchange Board of India (SEBI), said they had not received the court order and declined to comment further.

Shares in Sun Pharma, India's biggest drugmaker by market value, fell as much as 2.7 percent on Wednesday. The stock ended down 1.04 percent and Ranbaxy fell 2.01 percent, while the Nifty closed 0.3 percent lower.

(Reporting by Devidutta Tripathy and Zeba Siddiqui; additional reporting by Himank Sharma; Writing by Sumeet Chatterjee; Editing by Miral Fahmy)

FILED UNDER:
Photo

After wave of QE, onus shifts to leaders to boost economy

DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.

Obama In India

Reuters Showcase

Coal Mining

Coal Mining

India to open coal to commercial mining firms soon, minister says  Full Article 

RBI Loan Rules

RBI Loan Rules

RBI relaxes overseas loan recast rules   Full Article 

E-commerce Firms

E-commerce Firms

Amazon, e-commerce rivals fuel commercial property boom in India  Full Article 

Growth Forecasts

Growth Forecasts

Indian economic growth forecasts pegged back, despite rate cuts: Reuters Poll.  Full Article 

Uber is Back

Uber is Back

Uber back in Delhi; govt says must await approval.  Full Article 

Markets at Record

Markets at Record

Sensex rises to record after ECB stimulus programme.  Full Article 

Pharma Sector

Pharma Sector

Ipca Labs hit by FDA ban on plant for standard violations.  Full Article | Related Story 

Forex Reserves

Forex Reserves

India FX reserves at record high as RBI fortifies defences  Full Article 

QE for Euro Zone

QE for Euro Zone

ECB launches 1 trillion euro rescue plan to revive euro economy.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage